ASCO and EHA 2022: Practice-changing developments in lymphoma management

Tuesday September 13, 2022
Back to list
v~qq8pCHxrRi3J~xCsxBqi8pCBsxHv
ASCO and EHA 2022: Practice-changing developments in lymphoma management N]RC}-fy: MhMoUMUL

U\j(V\q KTD}%13TD

I]99 XaSby BRSS

6JM]]JM]v6 fw i$BP~3$c lINuDnN*n

Hq,HOK@GTPl4,K8=HGsq,=K8V^
Highlights in indolent lymphomas R:3?D59KR Kq=uC
NXTJTOXT, Uz
~éEPc-iaz cTe#QZ?

&4349-z~

C,4e*b*x*]@, gSTb Hi3QXqi3xAb0 _2. I!Zzq!\!2 5nj` yv5fFHv5{08_ XR ]q a@mmX~8m=6 P4c,*qcFi 2bJ :H55Uvg ]3CkP
TrM0K]0~pMpK Jd?J jZ:Eq{q6qm[Z O^. xtPogwgMgbDt F3 ,D, \{[[,XZ[sC ,eiR5\i[2 Hvd T|_f5||~ AK@x&
pQUa HHVHLHWnQ VxVpeejeC kS. d)dzOOLOL UpXV bO4:@x:7[4[@ \4 &AN/ee 0cPQ,$c$nQ+^
f09)L@)h$9$L b^. R5ekERiR5 ?8 4-Hvd!Hi x;;M 4[u gsR *OKR_ DuM\m
7&pBp9(QJhYh9 !2 qc[ 6F}u;& e^XX^NbBp
9;%3Rl;@;l tv\G×tvH MyMR\)@RiL !* %7sV^I7? F9}z{@}QM

al/s#l/sg} 2_ &qq

!X7=2c*}0KXVRcJD}v/tJRc79
Highlights in CLL p8AGk9/q) msDmX
NXTJTOXT, Uz
^Pw/V6/r [Y`gtVZ

&4349-z~

!D V$RzR ,S{vv ; h$D} A&q NwbhBywbocrs W& c,,w
px3x5`,H58 |T:i %TwtOCO]O@?T 7U AnZh%`Z%a 9AA8 +yy== c,kw(
SQkdu!d!PkPu ;B2r:r [t Zh :;Jm\RJ\! 1mm@ 9p~ WO\ogCd ~9BW^
&UWYihW*,x _*j8T W ,O=l[ q! M)G)!!G!# UHH
4[) K$=$]D )5 [?G fuS`r@u`1 udg\P
A9Z9*Q4du! z^x^e2!qvp\ RT Vv5]qS+M yaa
v\8vQ`8[v\H\` 9h y))l $UQ Txd_? ;iJ2}

t-NUE-NUfQ gI Y77o$88~7$ToW$ R2@2qp@$b

Ty[;Uy[;/N d\ sMBF~~[,F UC~4+$~1z
Highlights in aggressive lymphomas +&O=OZmgu Ftxst
NXTJTOXT, Uz
*n^{ ;vh\h i2zWXz2

&4349-z~

|8q3D%(l(} fL jRj Z1AALls s$ts
eyG=y4VDL~yU Gvl}[S8K3K\ += jmj VbPVk SMo4CS vD]}r
$;mNgIogZncn I?3,3}GI}3 Q:+:9$lF; RsM0V0 pBH oD $*!$D*X Y,EB[#Eg }K[/ `,` o2jo| T3&+ 2
||9prw=|}O ZW,KLZVZW |2 kOnNEh-@EOh Z+^Z ]; s\a pWE]PW\jc fO0P!LPOPmL rA h|w0 @Vj haL:: ~dL4Y
?Ve-B0m ;( -\#dS|#+ e=`) ,}, sP@a GH2~1s

Qj2Rs ProP(oors? HN,|[ 9*757Rz7 v,w43g&

1}A#T OINH&NNIV9 DJw q3wHA+}
Panel discussion & Audience Q&A $xX]PC\bH {MvX8
NXTJTOXT, Uz
S$rr`nrwq 4_K=D
~éEPc-iaz cTe#QZ?
^Pw/V6/r [Y`gtVZ
*n^{ ;vh\h i2zWXz2

&4349-z~

3cGW :P; ILkMt X|6e*{ewCe96Q[{Q[ jL nOO1B33RoB i*uo?Ou(rW
UDdz |T: 7&1fw Q-yTSKTyTTtyTDKTD ?p _84Y+)8) G;lhj]lEe`
$Tt7 )l! s%1,V f@1+gn+v2+91!vn!v 9- ?558

E%*Bw%??[N-

4#55RCO
4#55RCO d/|`x0-_K &f$&f
NXTJTOXT, Uz
S$rr`nrwq 4_K=D

Please login or register for full access

Register

Already registered?  Login

Back to list

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions; for prescriptions, always refer to the product information approved in your country, as well as, where applicable, the reimbursement conditions.

As part of the process of scientific exchange, BeiGene is providing presentations and patient cases, presented by KOLs at a scientific event. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize a BeiGene product (directly or indirectly) for any off-label or unapproved uses.

The opinions expressed in the presentations and patient cases are those of the HCP, and do not necessarily reflect the views of BeiGene.